Overview:
Epilepsy
can be classed as a major neurological disorder where the brain activity
becomes abnormal and triggers unusual behavior and sensations. The disorder is
discernible in young children and young adults and requires proper attention in
time before it can impact the body in an adverse way.
The Epilepsy Market Size is
expected to reach USD 1.10 Billion by 2032 at 7.2% CAGR during the forecast
period 2023-2032. The regional market is showing ample scope where a high
prevalence of the disease can inspire growth in diverse regions.
In
addition, the global market would benefit from the presence of countries in the
African region where various global bodies are trying to launch initiatives to
assist local doctors in curbing the diseases. However, poor economies can
detract the growth rate.
Competitive Landscape:
MRFR’s analysis of various companies to get close to factors that
can decipher the market growth and assist in the implementation of several
market strategies. The recording of these moves can inspire a better
understanding of the global scenario. Epilepsy
Market Players are.
GlaxoSmithKline PLC (U.K.),
LivaNova PLC (U.K.),
Medtronic PLC (Ireland),
Eisai Co. Ltd. (Japan),
Pfizer Inc. (U.S.),
NeuroPace Inc. (U.S.),
UCB SA (Belgium),
Johnson & Johnson Services Inc. (U.S.),
Novartis AG (Switzerland),
GW Pharmaceuticals PLC (U.K.),
Abbott Laboratories (U.S.).
These
companies are set on a path to solidify their own market stance and improve
scopes for expansion in the coming days.
Segmentation:
The
report on the epilepsy market encompasses
segments like by condition, diagnosis & treatment, and end-use to
facilitate an easy understanding of the market and gauge well how the regional
market would shape up in the coming years.
- By
condition, the market report on epilepsy
covers epilepsy
drug-resistant/intractable epilepsy and others. The former
had a market share of 29.5% in 2017. The global market for the segment can
provide ample growth opportunities as the requirement for drug-resistant
therapies can trigger better growth. The ‘others’ segment has a market
growth possibility of 7.83% CAGR during the forecast period.
- By
diagnosis and treatment, the market report on epilepsy
includes diagnosis and treatment. The diagnosis segment can be
sub-segmented into blood tests, imaging devices, and others. The treatment
segment includes neurostimulation
devices, anti-epileptic drugs, ketogenic diet,
brain surgery, and others. The treatment segment had 66.2% of the global
share in 2017. Cost-efficiency can be taken into consideration to
understand market growth possibilities.
- By
end-users, the epilepsy market can include
clinics, hospitals, diagnostic centers, ambulatory surgical centers, and
others. The hospital segment had a market share of 29.3% in 2017.
Regional Analysis:
The
global market, upon considering from a region-specific angle, can be segmented
into North America, Europe, and the Asia Pacific as major contributors. It also
covers Latin America and the Middle East & Africa (MEA) as countries
displaying moderate growth but with the potential to improve scenario. The
Americas has better market coverage and it had almost 41% of the global market
share in 2017. Europe is on a track to display 8.31% CAGR during the forecast
period. The regional market has potential to explore opportunities regarding
research and development, and it is getting backed by the constant influx of
investments. Countries like the UK, France, Germany, and others are
contributing much to take the regional market ahead in the coming years.
The
Asia Pacific (APAC) market is showing opportunities to score well past a
valuation mark of USD 2,046.57 million by 2023. Most of the traction to grow
forward would come from India, South Korea, and China where a large population
is triggering high ingress of treatments needed for that.
Related reports:
https://www.hongkongwomenorg.com/read-blog/199
About US:
Market
Research Future (MRFR) enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5Th Floor, New York,
New
York 10013
